Misonix Supports Uganda Spine Surgery Mission with Ultrasonic BoneScalpel™
FARMINGDALE, N.Y., Sept. 12, 2013
FARMINGDALE, N.Y., Sept. 12, 2013 /PRNewswire/ --Misonix, Inc. (NASDAQ:
MSON), an international surgical device company that designs, manufactures and
markets innovative therapeutic ultrasonic products for spine surgery, skull
based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic
surgery and other surgical applications, announced today that it supported
this year's Uganda Spine Surgery Mission organized by leading spine surgeon
Dr. Isador Lieberman, from the Texas Back Institute in Plano, TX, by donating
the use of the ultrasonic BoneScalpel during the performed spinal surgeries.
The Uganda Spine Surgery Mission was founded in 2006 by Dr. Mark Kayanja
(originally from Uganda) and Dr. Lieberman with the purpose of providing the
best possible spine care to Ugandan patients afflicted by infectious,
degenerative, traumatic and congenital spinal ailments. In addition, the
Mission strives to provide a fertile environment for the education of those
who serve these patients. Every summer an international team of surgeons and
nursing staff continues to donate several weeks of their time to perform as
many complex spine surgeries as possible in the visit's time frame. The spine
surgeries are often life-altering proceduresfor grateful patients who have
suffered from severe deformities over years, sometimes decades and who would
otherwise have no chance of ever undergoing surgical treatment.
This year's mission was from August 12 to 21 at Mbarara Regional Referral
Hospital which recently added a new hospital wing, including an Intensive Care
Unit, Emergency Department and Operating Theatres. A total of 120 patients
were screened upon arrival. The patients in some circumstances had waited for
days with their families for the team's arrival. Twelve of the sickest and
most pressing cases were carefully selected for surgery. The surgeries
themselves, complex enough from a medical perspective, were routinely
interrupted by power outages and other surprises that took the team's
continuous ingenuity to tackle.
The Misonix BoneScalpel™ is a unique ultrasonic osteotome for tissue-selective
bone dissection that encourages en-bloc bone removal and refined osteotomies
while sparing elastic soft tissue structures such as important nerves and
arteries. Therapeutic ultrasound is well known for its coagulative effects and
the BoneScalpel has been reported to substantially reduce blood loss in
multilevel spinal osteotomies.
Dr. Lieberman has been a long-term user of the BoneScalpel at Texas Health
Presbyterian Hospital in Plano, TX, and his experience of using it in over 120
surgeries was published in 2013 by the European Spine Journal. In Dr.
Lieberman's view, the BoneScalpel facilitates bone cutting in a wide variety
of spine surgeries. He sees it as a significant advancement over highspeed
drills that can dangerously wrap soft tissue matters around their spinning
tips or over manual mallets and chisels with their heavy pounding on the
spinal column. Using BoneScalpel, he has embraced a much more delicate and
tissue-specific approach to decompress injured nerve roots, up to the
development of newer cutting techniques that he is currently refining. Dr.
Lieberman has fully incorporated the BoneScalpel into his surgical routine,
using it on every case, in addition to his educational program for training
spine fellows and visiting surgeons.
"The Uganda mission has a very special place in my heart," stated Dr. Isador
Lieberman. "It goes back to the sincere request of a former fellow of mine,
Mark Kayanja, who inspired me to make a difference by coming with him to
Uganda to develop a spine surgery program for the less fortunate. Today, after
nine mission trips to Uganda, having provided spine care to well over 400
patients, and establishing lifelong relationships, I am deeply indebted to
him. By getting me involved in Uganda he has re-affirmed in my mind why I am a
"The addition of the BoneScalpel was of tremendous help this year," continues
the Canadian born surgeon. "Not only did I use it in all but one of the
surgeries, but I also used it to its fullest advantage when performing a
pedicle subtraction osteotomy and a hemi vertebrectomy, both very complex
procedures usually with a lot of bone bleeding. The BoneScalpel reduced the
bleeding significantly which helped to maintain the patients' fluid balance
and made these surgeries a lot easier in this extremely demanding
environment. The BoneScalpel has changed spine surgery in Uganda forever. I
am very grateful for the support from Misonix for this mission and hope for
many more to come."
Michael A. McManus, Jr., President and Chief Executive Officer of Misonix
said, "We are extremely pleased to be able to help support Dr. Lieberman and
the Uganda Spine Surgery Mission. The work being done by Dr. Lieberman in the
U.S. and Africa has been remarkable, not only in demonstrating the benefits of
BoneScalpel, but also in providing safe and advanced surgery benefits to his
many patients. His efforts to help the less fortunate are inspirational."
Misonix, Inc. designs, develops, manufactures and markets therapeutic
ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the
basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical
applications. Additional information is available on the Company's Web site at
Safe Harbor Statement
With the exception of historical information contained in this press release,
content herein may contain "forward looking statements" that are made pursuant
to the Safe Harbor Provisions of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. Investors are
cautioned that forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements made.
These factors include general economic conditions, delays and risks associated
with the performance of contracts, risks associated with international sales
and currency fluctuations, uncertainties as a result of research and
development, acceptable results from clinical studies, including publication
of results and patient/procedure data with varying levels of statistical
relevancy, risks involved in introducing and marketing new products, potential
acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such
activities, the timing of finding strategic partners and implementing such
relationships, regulatory risks including approval of pending and/or
contemplated 510(k) filings, the ability to achieve and maintain profitability
in the Company's business lines, and other factors discussed in the Company's
Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.
Misonix Contact: Investor Contact:
Richard Zaremba Joe Diaz
631-694-9555 Lytham Partners
SOURCE Misonix, Inc.
Press spacebar to pause and continue. Press esc to stop.